Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2009 Sep 22;7(3):464-71.
doi: 10.3390/md7030464.

Antibacterial activity of 2-(2',4'-dibromophenoxy)-4,6-dibromophenol from Dysidea granulosa

Divya M P Shridhar  1 , Girish B Mahajan, Vijayendra P Kamat, Chandrakant G Naik, Rajashri R Parab, Nidhi R Thakur, Prabhu D Mishra
Affiliations
Comparative Study

Antibacterial activity of 2-(2',4'-dibromophenoxy)-4,6-dibromophenol from Dysidea granulosa

Divya M P Shridhar et al. Mar Drugs. .

Abstract

2-(2',4'-Dibromophenoxy)-4,6-dibromophenol isolated from the marine sponge Dysidea granulosa (Bergquist) collected off the coast of Lakshadweep islands, Indian Ocean, exhibited potent and broad spectrum in-vitro antibacterial activity, especially against methicillin resistant Staphylococcus aureus (MRSA), methicillin sensitive Staphylococcus aureus (MSSA), vancomycin resistant Enterococci (VRE), vancomycin sensitive Enterococci (VSE) and Bacillus spp. Minimal inhibitory concentration (MIC) was evaluated against 57 clinical and standard strains of Gram positive and Gram negative bacteria. The observed MIC range was 0.117-2.5 microg/mL against all the Gram positive bacteria and 0.5-2 microg/mL against Gram negative bacteria. The in-vitro antibacterial activity observed was better than that of the standard antibiotic linezolid, a marketed anti-MRSA drug. The results establish 2-(2',4'-dibromophenoxy)-4,6-dibromophenol, as a potential lead molecule for anti-MRSA and anti-VRE drug development.

Keywords: 2-(2′,4′-dibromophenoxy)-4,6-dibromophenol; Dysidea granulosa; antibacterial activity; methicillin resistant Staphylococcus aureus; vancomycin resistant enterococci.

PubMed Disclaimer

Figures

Figure1
Figure1
Structure of 2-(2′,4′-dibromophenoxy)-4,6-dibromophenol.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Menichetti F. Current and emerging serious Gram-positive infections. Clin Microbiol Infect. 2005;11:22–28. - PubMed
    1. Loddenkemper R, Sagebiel D, Brendel A. Strategies against multidrug-resistant tuberculosis. Eur Respir J. 2002:66S–77S. - PubMed
    1. Aeschlimann JR, Rybak MJ. Pharmacodynamic analysis of the activity of quinupristin-dalfopristin against vancomycin-resistant Enterococcus faecium with differing MBCs via time-kill-curve and postantibiotic effect methods. Antimicrob Agents Chemother. 1998;42:2188–2192. - PMC - PubMed
    1. Tsiodras S, Gold HS, Sakoulas G. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet. 2001;358:207–208. - PubMed
    1. Mutnick AH, Enne V, Jones RN. Linezolid resistance since 2001: SENTRY antimicrobial surveillance program. Ann Pharmacother. 2003;37:769–774. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources